Please assess the completion status of the following clinical trial:

Trial Title: Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Melanomas that arise on chronically sun damaged skin and have pathologic evidence of solar elastosis~* History of primary mucosal or acral/lentiginous melanoma~* Histologically documented stage IV metastatic melanoma~* ECOG performance status 0,1, or 2~* Estimated life expectancy of 6 months or greater~* Age 18 years or older~* Creatinine \< 1.5 x ULN~* ANC \> 1500 ul~* Platelets \> 100,000 ul~* Total bilirubin, AST, and ALT \< 2 x ULN~* Amylase and lipase \< 1.5 x ULN~* C-kit mutation documented from either primary or metastatic tumor site~* \> 4 weeks from prior chemotherapy or investigational drug~* At least one measurable site of disease as defined by at least 1 cm in greatest dimension~Exclusion Criteria:~* Severe and/or uncontrolled medical disease~* Pregnant or nursing mothers~* Any other significant medical, surgical, or psychiatric condition that my interfere with compliance~* Patient is \< 5 years free of another primary malignancy except: basal cell skin cancer or a cervical carcinoma in situ~* Concurrent treatment with Warfarin~* Prior treatment with c-kit inhibitor~* Patient with Grade III/IV cardiac problems as defined by NYHA criteria~* No H2 blockers or proton pump inhibitors~* Known brain metastasis~* Known chronic liver disease~* Known diagnosis of HIV infection~* Previous radiotherapy to \> 25% of the bone marrow~* Major surgery within 2 weeks prior to study entry~* Patient has received any other investigational agent within 28 days of first study drug dosing~* Chemotherapy within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Imatinib

Based on this trial design, predict the completion outcome and termination type (if applicable).